

**CLAIM AMENDMENTS**

1-4. (canceled)

5. (currently amended): A controlled release system comprising a temperature sensitive polymer of ~~claim 1~~ having a lower critical solution temperature (LCST) that changes during incubation in an aqueous medium, which polymer is a homo- or interpolymer of an (N-(2-hydroxypropyl) methacrylamide lactate), and  
an active ingredient.

6. (currently amended): The controlled release system of ~~claim 4~~ claim 5, wherein the polymer is in the form of a polymeric micelle comprising a hydrophilic block.

7. (original): The controlled release system of claim 6, wherein the hydrophilic block comprises poly(ethyleneglycol).

8. (original): The controlled release system of claim 5 or 6, wherein the system is in the form of a hydrogel.

9. (currently amended): The controlled release system of ~~claim 5 or 6~~ claim 8, wherein the hydrogel is an ABA block copolymer, wherein block A is the temperature sensitive polymer of ~~claim 1~~ claim 5 and block B is a hydrophilic polymer.

10. (original): The controlled release system of claim 9, wherein block B is PEG.

11. (original): A targeting drug composition, comprising a drug and particles of a controlled release system according to claim 5, wherein the particles have an average diameter of less than 100 nm.

12. (original): The targeting drug composition of claim 9 further comprising a homing device.